


**Aim:** To reduce delays in analgesia administration to better manage pain and improve outcomes in patients presenting with Sickle Cell Pain Crisis.



**Aim:** To reduce delays in analgesia administration to better manage pain and improve outcomes in patients presenting with Sickle Cell Pain Crisis.

## NOTES:

**Note 1. Signs/Symptoms** consistent with Sickle Cell Pain crisis includes extremity pain, back pain, abdomen or chest wall pain often without overlying skin or joint changes.

1. Reported pain remains the gold standard for pain assessment
2. Assess vital signs and lab values (CBC, retic, T/D bili, LDH, BMP)
3. Differential diagnosis: Skin/Soft Tissue Infection, osteomyelitis, vascular necrosis, trauma, gout, arthritis, DVT/PE, MI, stroke, migraine, meningitis, stroke, acute cholecystitis, pelvic inflammatory disease, constipation. Please evaluate and exclude etiology from standard of care (i.e. abdominal pain appendicitis etc.)
4. Please consider accompanying SCD related conditions: Fever, acute chest syndrome, acute multi-organ failure, acute splenic or hepatic sequestration, delayed hemolytic transfusion crisis, renal infarct, stroke. If concern for stroke, then excluded from this guideline and move to ED suspected stroke guideline, consulting heme STAT and other consultants per stroke guideline.

**Note 2. Possible triggers of Sickle Pain include** Infections, dehydration, stress, menses, alcohol, rapid temperature change, prior steroid course (rebound pain).

### Note 3. Mild vs Moderate vs Severe pain episodes:

Reported pain remains gold standard for pain assessment. Utilize pain scores to help assess pain level. Because each patient has a unique experience for each pain scale number, also assess how patient would rate their score of mild (generally 1-3), moderate (generally 4-6), or severe pain (generally 7-10).

### Note 4. Dosing of pain medication:

1. Acetaminophen 15 mg/kg (Max 650 mg) by mouth
2. Intranasal (IN) Fentanyl 1-2 mcg/kg (Max 100 mcg) if  $\geq 3$  yrs old. Can repeat every 1 hour
3. Ibuprofen 10 mg/kg (Max 600 mg) by mouth
4. Ketorolac 0.5 mg/kg (Max 15 mg) IM or IV; must be  $\geq 6$  hours from last NSAID dose (Oral ketorolac is **not** on formulary)
5. Oxycodone 0.05 - 0.1 mg/kg (Max 10 mg) by mouth
6. Morphine 0.1 mg/kg (max 6 mg) IV

### Note 5. Patient-Controlled Analgesia (PCA) Pumps

1. Hematology preps STAT PCA order which will be initiated once admitted. Simultaneously, provider will place order for naloxone drip at 2 mcg/kg/h. As needed naloxone bolus dose for oversedation will automatically order within the EMR secondary to the PCA order.
2. PCA Medications and Dosing
  - If patient has not had PCA previously, then start morphine PCA. Otherwise, per pain plan or last PCA used during hospital stay
  - Morphine PCA: morphine 0.015 mg/kg/h continuous infusion (max 0.75 mg/h), 0.015 mg/kg demand dose (max 0.75 mg), 10-minute lockout, maximum hourly dose = 0.075 mg/kg/h (max 3.75 mg/h)
  - All patients on opioid PCA should have naloxone drip starting at 2 mcg/kg/h
  - Side effects (treatment options) include:
    - Pruritus (diphenhydramine, naloxone drip)
    - Nausea/vomiting (ondansetron)
    - Constipation (polyethylene glycol, senna, bisacodyl, docusate)
    - Respiratory depression (naloxone 0.01 mg/kg/dose (Max 0.4mg) IV or IN to alleviate sedation – not reverse analgesia)

**Aim:** To reduce delays in analgesia administration to better manage pain and improve outcomes in patients presenting with Sickle Cell Pain Crisis.

**Note 6. Complications of sickle cell that would inhibit discharge:**

1. Respiratory symptoms/hypoxia concerning for Acute Chest Syndrome
2. Focal neurologic symptoms or unevaluated headache
3. Significant marrow suppression (Hgb below baseline without adequate reticulocytosis)
4. Evidence of splenic sequestration
5. Priapism
6. Acute infectious concerns requiring admission

**Note 7. Patient discharge education and follow-up:**

1. Continue oral ibuprofen and acetaminophen every 6 hours for 2-3 days after opioid discontinued. Advise family of timing for next doses
2. Ensure family has 12 doses of oral Oxycodone (3 days of q6 hours or 4x/day dosing) at time of d/c unless otherwise directed by pain plan. Advise family of timing for next doses.
3. Review non-pharmacologic pain management options
  - o Deep Breathing, Progressive Muscle Relaxation, Imagery, Self-Hypnosis, Aromatherapy, Acupressure, Distraction, Massage, Application of Heat, Guided Imagery
4. Ask family to call the following day to give an update on symptoms; patient can also call sooner if worsening (if Mon-Fri, patient should call heme clinic; if Sat-Sun or overnight, patient should call the on-call provider). Hematologist will also notify Heme RN as well to reach out during weekdays.

**WORKGROUP:** S Fritch Lilla, J Arms, K Greenwood, R Sicoli, S Schwantes, M Raschka, K Brunsberg, P Page, E Morhack, C Kenefick, S McCann, K Lavander, C Wegmann, H Nelson, T Nienow, C Juarez-Sweeney, J Olsen, L Leming, Agrimson L, Vikla J, Scribner-O'Pray M, Sakamoto D

**REFERENCES:**

1. Brandow A, et al, American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv* (2020) 4 (12): 2656–2701 <https://doi.org/10.1182/bloodadvances.2020001851>
2. Children's Hospital of Philadelphia, Umana J, et al., Emergency Department Clinical Pathway for the Evaluation/Treatment of Children with Sickle Cell Disease and Pain. Posted: July 2010  
Revised: March 2024. Available from [Sickle Cell Disease with Pain Clinical Pathway — Emergency Department | Children's Hospital of Philadelphia \(chop.edu\)](#)
3. Seattle Children's Hospital, Bender, M., Burns, B., Crandall, C., Dassler, A., Herrman, A., Hrachovec, J., Lo, M., Reichert, E., Staples, S., Thomas, A., Migita, D., 2024 January. Sickle Cell ED Vaso-occlusive Pain Pathway. Available from [CSW Sickle Cell - ED Vaso-occlusive Pain Pathway \(seattlechildrens.org\)](#)
4. New England Pediatric Sickle Cell Consortium: Management of Acute Pain in Pediatric Patients with Sickle Cell Disease (Vaso-Occlusive Episodes). Available from Microsoft Word - PAIN CPG 2-09.doc (nepssc.org)